Overall, the ACSL1 low-expression subgroup of ccRCC might be suitable for PI3K pathway inhibitors, while the ACSL1 high-expression subgroup of ccRCC might be more sensitive to Sunitinib and Pazopanib. Here, ACSL1 is linked to nonpapillary renal cell carcinoma.